🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

the book the lesson

After ASCO, so much to discuss about breast cancer! Which agents, when, for how long, in whom? Get all the answers at our renowned 2-day breast program with outstanding faculty from Dana-Farber & Mass General Cancer Center Harvard Medical School Inperson and virtual options cmecatalog.hms.harvard.edu/breast-cancer-…

one of Steve Jobs' best lines. simplicity is so hard.

Great work by Eva Blondeaux and colleagues 🇮🇹 published on ESMO Open!

Such an honor to have Dr. Beatrice Wiafe-Addai visiting Dana-Farber for few days. Interesting prospective of cancer care from 🇬🇭 Ghana where drug armamentarium is so limited. #cancerdisparity #westafrica Dana-Farber News Dana-Farber’s Breast Oncology Center

Great line

Top companies from ASCO 2025, highlighted by LARVOL CLIN. Follow us and get the latest #ASCO25 updates: t.ly/7TCD6 #LARVOL #ASCO2025 #Oncology #CancerResearch #CancerData #OncologyInsights #CancerCare | LARVOL | Matteo Lambertini, MD PhD | Mark Lewis, MD, FASCO | Vivek Subbiah, MD |

We’re proud to be recognized by Newsweek as one of America’s Greatest Workplaces in Healthcare 2025! Thank you to our incredible staff who makes Dana-Farber such a special place to work. View the full list here: bit.ly/3SH7cC6

T-DXd Plus Pertuzumab Could Disrupt First-Line SOC in HER2+ Metastatic Breast Cancer Dana-Farber News ASCO #ASCO25 #bcsm #oncology onclive.com/view/t-dxd-plu…

Here in Canada, Prof. Senan reminds us of an urban myth. 🇨🇦 #SABRCAN25 ascopubs.org/doi/10.1200/JC…

Final results of IMpassion031 by Dr. E Mittendorf et al. published in Nature Medicine. Perioperative atezo, added to chemo, led to more favorable survival outcomes for eTNBC. Most pts cleared ctDNA. Poorest outcomes observed for the few pts with RD & ctDNA+. nature.com/articles/s4159…

The Top Most Active Cancer Institutes that were leading the conversation during the ASCO 2025, ranked based on oncologists' reactions and engagement on X. Follow us for more #ASCO25 updates: t.ly/7TCD6 #LARVOL #CancerResearch #Oncology #CancerData

So glad to have you with us this week, Akhil. Keep up the terrific work!

Paolo Tarantino Thanks a lot. you are ever so passionate about the work you do, it was great interacting . You continue to inspire us !

Interesting phase 2 trial of 1L taxol/atezo/beva for (mostly) PDL1- mTNBC (n=100) out in Nature Medicine. ORR 63%, mPFS 11 months, mOS 27 months. VEGF inhibition is SO back in breast oncology. Glad to have had the chance to review this paper. nature.com/articles/s4159…

I’ve noticed a lot of discordance between real world studies looking at treatment attrition in mBC. Poll for med oncs: How many of the patients with mBC you care for do NOT manage to receive a new line of chemo after discontinuing the first line of chemo?

informative censoring vs ITT analyses.-a problem for all studies of exercise in cancer patients I suspect

I'm Riding for Roswell to raise funds for cancer care! Please consider donating to support our work to end cancer! Roswell Park give.roswellpark.org/site/TR/Specia…

extremely interesting data showing how ~3% of normal breast cells have chromosomal abnormalities resembling cancer - increasing with age. most people are not aware that no researcher knows what the exact border between cancer & normal tissue is, when normal ends & cancer starts